Inhibitors, Agonists, Screening Libraries

Data Sheet

Product Name: Frentizole
Cat. No.: HY-15374
CAS No.: 26130-02-9
Molecular Formula: C_{15}H_{13}N_{3}O_{2}S
Molecular Weight: 299.35
Target: Amyloid-β
Pathway: Neuronal Signaling
Solubility: DMSO: ≥ 3 mg/mL

BIOLOGICAL ACTIVITY:
Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the Aβ-ABAD interaction.

IC50 value:
Target: Aβ-ABAD interaction

PROTOCOL (Extracted from published papers and Only for reference)
Animal administration [2] ND4 specific-pathogen-free male mice weighed 12 to 14 g for virus studies and 18 to 20 g for all other studies. Frentizole and azathioprine were individually tested. Each drug was suspended separately in saline by grinding in a Tenbrook tissue homogenizer. The final drug suspensions (0.25 ml) were administered subcutaneously to the nuchal neck region. Drugs were administered daily for 10 days prior to inducing infection. In all cases, except the 3-day Pseudomonas experiments, treatment was continued until the termination of each group of experiments by parameters described below. For each dose level of drugs tested, 10 to 20 animals were used.

References:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA